Taku Closes Financing

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 06/23/16 -- Taku Gold Corp. (CSE: TAK) ("Taku" or the "Company") is pleased to announce the closing of its non-brokered private placement totalling $400,000. These funds were raised through the issuance of 5,000,000 units at a price of $0.08 per unit, each unit consisting of one common share and one share purchase warrant entitling the holder thereof to acquire one additional common share of the Company for a period of two years at a price of $0.12. The shares issued pursuant to the private placement, and any shares to be issued on exercise of the share purchase warrants, are subject to a hold period expiring October 19, 2016.

Commissions totalling $10,850 were paid to CIBC Wood Gundy, NBCN Inc. and Canaccord Financial Ltd., as consideration for arranging a portion of the private placement.

The funds raised by way of the private placement will be used for general working capital purposes.

About Taku Gold Corp.

Taku Gold Corp. (www.takugold.com) is a mineral resource company focused on the exploration and development of precious metal properties in Canada with a particular emphasis on the White Gold District of the Yukon Territory and the Tagish Lake region of Northern British Columbia.

On Behalf of the Board,

Zachery Dingsdale, President and CEO, Taku Gold Corp.

Follow Taku Gold On:
Facebook: www.facebook.com/takugold
Twitter: www.twitter.com/takugoldcorp
YouTube: www.youtube.com/user/TakuGold
Flickr: www.flickr.com/photos/takugold/

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts:
Taku Gold Corp.
Zachery Dingsdale
President and CEO
800 610-9552
604 642-0116 (FAX)
[email protected]
www.takugold.com

Source: Taku Gold Corp.

You May Also Be Interested In

• Takeda's zasocitinib beats deucravacitinib in psoriasis study
• Oppenheimer sees little strategic case for Tesla-SpaceX merger
• Guardant Health receives FDA approval for companion diagnostic test